Protection conferred by booster vaccine doses in hospitalized patients with COVID-19 during the SARS-CoV-2 Omicron BA.2 and BA.5 epidemics from 2022 to 2023 in Greece
Helena C.Maltezou Amalia Karapanou Dimitrios Basoulis Kyriakos Souliotis Periklis Panagopoulos Dimitrios Hatzigeorgiou Garyfalia Poulakou Konstantinos N.Syrigos Nikolaos V.Sipsas Maria N.Gamaletsou Maria Chini Vasileios Petrakis Vasiliki Rapti Theodoros V.Giannouchos Eleni Karantoni Konstantinos Kounouklas Panagiota Stamou
感染医学(英文)2024,Vol.3Issue(4):314-321,8.
感染医学(英文)2024,Vol.3Issue(4):314-321,8.DOI:10.1016/j.imj.2024.100144
Protection conferred by booster vaccine doses in hospitalized patients with COVID-19 during the SARS-CoV-2 Omicron BA.2 and BA.5 epidemics from 2022 to 2023 in Greece
Protection conferred by booster vaccine doses in hospitalized patients with COVID-19 during the SARS-CoV-2 Omicron BA.2 and BA.5 epidemics from 2022 to 2023 in Greece
摘要
关键词
COVID-19/Hospitalization/Booster doses/Risk factors/Adverse outcomesKey words
COVID-19/Hospitalization/Booster doses/Risk factors/Adverse outcomes引用本文复制引用
Helena C.Maltezou,Amalia Karapanou,Dimitrios Basoulis,Kyriakos Souliotis,Periklis Panagopoulos,Dimitrios Hatzigeorgiou,Garyfalia Poulakou,Konstantinos N.Syrigos,Nikolaos V.Sipsas,Maria N.Gamaletsou,Maria Chini,Vasileios Petrakis,Vasiliki Rapti,Theodoros V.Giannouchos,Eleni Karantoni,Konstantinos Kounouklas,Panagiota Stamou..Protection conferred by booster vaccine doses in hospitalized patients with COVID-19 during the SARS-CoV-2 Omicron BA.2 and BA.5 epidemics from 2022 to 2023 in Greece[J].感染医学(英文),2024,3(4):314-321,8.基金项目
This work was supported in part by an independent research grant(4900013655)from Novavax,Inc.The opinions expressed in this article are those of the authors and do not necessarily represent those of their institutions or Novavax,Inc. (4900013655)